Skip to main content
SpringerLink
Log in
Book cover

Geriatric Oncology pp 1–13Cite as

Chronic Myelogenous Leukemia and Myeloproliferative Disorders in Older Adults

  • 43 Accesses

Abstract

Chronic myeloid leukemia (CML) and other myeloproliferative neoplasms are more often diagnosed in people aged above 65. CML is more common in older adults, frequently diagnosed among people aged 65–74. Given the large proportion of older adults with these diseases, it is of interest to pay higher attention in special physiologic and comorbidity conditions found in older people. Plenty of data can be obtained from clinical trials in these diseases about tolerance, side effects, and outcome in elderly people when compared with younger people. Comorbid conditions are now being assessed in these chronic myeloproliferative diseases, with a strong correlation with toxicity and survival. Quality of life may also be improved with the new target therapy strategies approved not only in CML but also in primary myelofibrosis patients.

This is a preview of subscription content, log in via an institution.

References

  • Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447–59.

    Article  PubMed  Google Scholar 

  • Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the european LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(Suppl 2):S141–7.

    Article  PubMed  Google Scholar 

  • Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet. J Clin Oncol. 2011a;29(6):761–70.

    Article  PubMed  PubMed Central  Google Scholar 

  • Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011c;29(23):3179–84.

    Article  PubMed  Google Scholar 

  • Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015;5:e337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17(9):2954–70.

    Article  CAS  PubMed  Google Scholar 

  • Bjerrum L, Søgaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol. 1998;54(3):197–202.

    Article  CAS  PubMed  Google Scholar 

  • Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.

    Article  CAS  PubMed  Google Scholar 

  • Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96(10):1457–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ESWHO. Classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  • Cervantes F. How I treat. Blood. 2014;124(17):2635–42.

    Article  CAS  PubMed  Google Scholar 

  • Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. System. 2009;113(13):2895–901.

    CAS  Google Scholar 

  • Cervantes F, Correa JG, Pérez I, García-Gutiérrez V, Redondo S, Colomer D, Jiménez-Velasco A, Steegmann JL, Sánchez-Guijo F, Ferrer-Marín F, Pereira A, Osorio S; CML Spanish Group (GELMC)) Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol 2016. http://link.springer.com/article/10.1007%2Fs00277-016-2839-z. https://doi.org/10.1007/s00277-016-2839-z Last Accessed 29 Nov 2016.

  • Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer. 1991;67(11):2926–30.

    Article  CAS  PubMed  Google Scholar 

  • Cortes JE, Jean Khoury H, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91(6):606–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.

    CAS  PubMed  Google Scholar 

  • Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, Fava C, Angelucci E, Mandelli F, Baccarani M. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Ann Hematol. 2016;95(2):211–9.

    Article  CAS  PubMed  Google Scholar 

  • Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35(3):181–200.

    Article  CAS  PubMed  Google Scholar 

  • Fava C, Saglio G. Ponatinib for chronic myeloid leukaemia: future perspectives. Lancet Oncol. 2016;17(5):546–7.

    Article  PubMed  Google Scholar 

  • Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.

    Article  PubMed  Google Scholar 

  • Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162(2):229–39.

    Article  CAS  PubMed  Google Scholar 

  • Harrison CN, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari HA. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850–8.

    Article  CAS  PubMed  Google Scholar 

  • Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–92.

    Article  CAS  PubMed  Google Scholar 

  • Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336–43.

    Article  CAS  PubMed  Google Scholar 

  • Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

  • Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  • Iurlo A, Ubertis A, Artuso S, Bucelli C, Radice T, Zappa M, Cattaneo D, Mari D, Cortelezzi A. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med. 2014;25(1):63–6.

    Article  PubMed  Google Scholar 

  • Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 2016; 7(48):80083–90 doi: https://doi.org/10.18632/oncotarget.11657 [Epub ahead of print]

  • Janssen-Heijnen ML, Houterman S, Lemmens VEPP, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach. Crit Rev Oncol Hematol. 2005;55:231–40.

    Article  PubMed  Google Scholar 

  • Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65(2):132–9.

    Article  CAS  PubMed  Google Scholar 

  • Kong H, Liu Y, Luo S, Li Q, Wang Q. Frequency of calreticulin (CALR) mutation and its clinical prognostic significance in essential thrombocythemia and primary myelofibrosis: a meta-analysis. Intern Med. 2016;55(15):1977–84.

    Article  PubMed  Google Scholar 

  • Landolfi R, Marchioli R. European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Semin Thromb Hemost. 1997;23(5):473–8.

    Article  CAS  PubMed  Google Scholar 

  • Lang K, McGarry LJ, Huang H, Dorer D, Kaufman E, Knopf K. Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked seer-medicare data. Clin Lymphoma Myeloma Leuk. 2016;16(5):275–85.

    Article  PubMed  Google Scholar 

  • Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, Salaroli A, De Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G. Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a “real-life” patient population with chronic myeloid leukaemia. Hematol Oncol 2015. doi: https://doi.org/10.1002/hon.2274., http://onlinelibrary.wiley.com/doi/10.1002/hon.2274/abstract;jsessionid=E6ECA9F795EE28ABB8C5C2327A36B066.f01t02. Last Accessed 29 Nov 2016.

  • Marchioli R. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.

    Article  PubMed  Google Scholar 

  • Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.

    Article  CAS  PubMed  Google Scholar 

  • Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  • Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89(7):2319–27.

    CAS  PubMed  Google Scholar 

  • Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S. Comorbidities predict worse prognosis in patients with primary myelofibrosis. Cancer. 2014;120(19):2996–3002.

    Article  PubMed  PubMed Central  Google Scholar 

  • Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.

    Article  CAS  PubMed  Google Scholar 

  • Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.

    Article  CAS  PubMed  Google Scholar 

  • Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67(2):124–32.

    Article  PubMed  PubMed Central  Google Scholar 

  • Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D’Emilio A, Santini V, Girasoli M, Lorenzo RD, Bernardi S, Palma AD, Cesana BM, Soverini S, Martinelli G, Rosti G, Baccarani M. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J. 2015;5:e347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Curr Med Res Opin. 2016;32(5):817–27.

    Article  CAS  PubMed  Google Scholar 

  • Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–99.

    CAS  PubMed  Google Scholar 

  • Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–73.

    Article  CAS  PubMed  Google Scholar 

  • Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573–82.

    Article  CAS  PubMed  Google Scholar 

  • Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014a;124(16):2507–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014b;28(7):1407–13.

    Article  CAS  PubMed  Google Scholar 

  • Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014c;89(8):E121–4.

    Article  CAS  PubMed  Google Scholar 

  • Uemura M, Imataki O, Kawachi Y, Kawakami K, Hoshijima Y, Matsuoka A, Kadowaki N. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor. Int J Hematol. 2016;104(5):621–7.

    Article  CAS  PubMed  Google Scholar 

  • Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–35.

    Article  PubMed  PubMed Central  Google Scholar 

  • Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yancik R, Ganz PA, Varricchio CG, et al. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19(4):1147–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Fundación Jiménez Díaz University Hospital, Health Research Institute IIS-FJD, Autonomous University of Madrid, Madrid, Spain

    Raul Cordoba & Juan-Manuel Alonso

  2. Department of Hematology, University Hospital Ramón y Cajal, Madrid, Spain

    Valentin Garcia-Gutierrez

Authors
  1. Raul Cordoba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentin Garcia-Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan-Manuel Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raul Cordoba .

Editor information

Editors and Affiliations

  1. Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, Florida, USA

    Martine Extermann

Section Editor information

  1. Comprehensive Cancer Center of Wake Forest University, Winston-Salem, USA

    Heidi Klepin

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Cordoba, R., Garcia-Gutierrez, V., Alonso, JM. (2018). Chronic Myelogenous Leukemia and Myeloproliferative Disorders in Older Adults. In: Extermann, M. (eds) Geriatric Oncology . Springer, Cham. https://doi.org/10.1007/978-3-319-44870-1_45-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44870-1_45-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44870-1

  • Online ISBN: 978-3-319-44870-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Chronic Myelogenous Leukemia and Myeloproliferative Disorders in Older Adults
    Published:
    11 January 2018

    DOI: https://doi.org/10.1007/978-3-319-44870-1_45-2

  2. Original

    Chronic Myelogenous Leukemia and Myeloproliferative Disorders in Older Adults
    Published:
    23 December 2017

    DOI: https://doi.org/10.1007/978-3-319-44870-1_45-1

Search

Navigation